INTRODUCTION
According to the ' protein only ' hypothesis, transmissible spongiform encephalopathies are caused by a conformational conversion of the α-helix-rich, protease K-sensitive normal cellular prion protein (PrP C ) to a β-sheet-rich, relatively protease K-resistant and infectious form commonly known as scrapie PrP (PrP Sc ) [1] [2] [3] [4] . PrP C is a glycosylphosphatidylinositol-anchored cell-surface membrane protein encoded by the Prnp gene [5] [6] [7] . Mature, full-length human PrP C spans from residues 23 to 231 of the predicted polypeptide with two highly conserved potential Nlinked glycosylation sites [5] [6] [7] . NMR studies have revealed that the N-terminus of PrP C is very flexible and lacks any regular secondary structures, while the C-terminal region contains a well-defined folded domain [8] [9] [10] .
Despite earlier reports of neurological deficiencies in PrP C−/− mice [11] , more recent studies reveal that PrP C−/− mice are normal [12] . Thus the normal function(s) of PrP C remain unclear. Accumulated evidence suggests that PrP C is a metal-binding protein, and may function as a metal transporter [13, 14] . Binding of Cu# + also enables PrP C to acquire a superoxide dismutase (SOD)-like antioxidant activity [15] , suggesting that PrP C may also participate in the regulation of oxidative stress [16] . Other ligands that have been reported to bind PrP C include laminin [17] , laminin receptor [18] , nucleic acid [19, 20] , plasminogen [21] and neural cell-adhesion molecule (N-CAM) [22] .
Earlier studies suggested that brain-derived PrP C binds polyanions such as glycosaminoglycans (GAGs) [23,23a] . This is supported by the finding that injection of some GAGs prolongs the incubation period in experimentally infected animals [24, 25] . In addition, immunohistochemical staining of brain tissues from infected animals and Creutzfeldt-Jakob disease patients shows co-localization of GAGs and PrP Sc [26] . Cell culture studies demonstrated that some polyanions could induce the internalization of cell-surface PrP C [27] . There are also studies Abbreviations used : ABTS, 2,2h-azinobis-(3-ethylbenzothiazoline-6-sulphonic acid) ; GAG, glycosaminoglycan ; HRP, horseradish peroxidase ; mAb, monoclonal antibody ; PrP C , normal cellular prion protein ; PrP Sc , scrapie PrP ; rPrP, recombinant human PrP ; SOD, superoxide dismutase. 1 To whom correspondence should be addressed (e-mail mxs92!po.cwru.edu).
fashion. We found that GAGs specifically bind to a synthetic peptide corresponding to amino acid residues [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in the N-terminus of rPrP. We further demonstrated that while both wild-type PrP C and an octapeptide-repeat-deleted mutant PrP produced by transfected cells bound heparin at the cell surface, the PrP N-terminal deletion mutant and non-transfectant control failed to bind heparin. Binding of heparin to wild-type PrP C on the cell surface results in a reduction of the level of cell-surface PrP C . These results provide strong evidence that PrP C is a surface receptor for GAGs.
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suggesting that heparan sulphate greatly increased the infectivity of protease-resistant PrP [28] , and stimulated PrP Sc formation [29] . In contrast, other studies have shown that polyanions inhibit PrP Sc replication in itro [30, 31] . The inhibitory mechanism postulated is that the polyanions block PrP Sc replication by directly inhibiting the PrP Sc binding to PrP C . There is evidence that proteoglycans such as heparan are involved in PrP interaction with one of its potential receptors (ligands), the laminin receptor [32] . More recently, it has been reported that recombinant mouse PrP produced in mammalian cells also bind GAGs and this binding was enhanced by divalent cations [33] . Another study with recombinant hamster PrP and small human PrP fragments has identified three heparin-binding sites at the Nterminal region of PrP. In this study, it was reported that copper reduced rather than enhanced the binding of PrP to GAG [34] . The reasons for this discrepancy are not known. Collectively, these results suggest intimate and complex relationships between PrP C , PrP Sc , metals and GAGs.
In this study, we used recombinant human PrP (rPrP) proteins, including full-length rPrP #$ -#$" , N-terminally truncated rPrP *! -#$" , C-terminally truncated rPrP #$ -"%& and affinity-purified brainderived native PrP C species, to study PrP C binding to GAGs in greater detail. We also studied the effects of divalent cations on the binding of different PrP C species to GAGs. In addition, we identified a motif on PrP C that is responsible for GAG binding. Finally, since PrP C is normally a cell-surface protein, we also investigated whether cell-surface PrP C binds GAGs.
MATERIALS AND METHODS rPrP and cell lines
The generation, purification and characterization of full-length rPrP #$ -#$" , N-terminally truncated rPrP *! -#$" and C-terminally truncated rPrP #$ -"%& have been described in detail [35] . All the recombinant human PrP proteins were kindly provided by Dr W. Surewicz (Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH, U.S.A.). M17 is the parental neuroblastoma cell line that does not express PrP C [36] . Stable M17 transfectants, with the episomal vector CEP4β containing different PrP coding sequences, were also used in this study. They were designated WV, VT and δ8. WV contains the full-length human PrP coding sequence with Val at codon 129, VT contains a mutated PrP coding sequence with a deletion of codons 23-90, and δ8 contains a PrP mutant with a deletion of codons 51-90. Both deletion mutants were constructed using the Bio-Rad Muta-Gene phagemid in itro mutagenesis kit. The primer used for VT is 5h-GGAGTGA-CCTGGGCCTCTGC*GGTCAAGGAGGTGGC-3h, and the primer for δ8 is 5h-GGCAACCGCTACCCA*CAAGGAGGT-GGCACC-3h. The * indicates the site of the loop out.
Preparation of full-length and N-terminally truncated PrP
C Human brain tissues of the front cortex were obtained from autopsies of non-prion-disease cases. Brain homogenate was prepared in 10 vol. of lysis buffer (10 mM Tris, 150 mM NaCl, 1 % Nonidet P-40, 0.5 % deoxycholate and 5 mM EDTA, pH 8.0) in the presence of 1 mM PMSF. After centrifugation at 11 000 g for 10 min with a microcentrifuge, the supernatants were collected and stored at k80 mC. The PrP C present in brain homogenate was separated into full-length and N-terminally truncated fractions with anti-PrP monoclonal antibody (mAb) coupled Protein G immunoaffinity columns.
The anti-PrP mAb-coupled columns were prepared with the Seize X Protein G Immunoprecipitation kit (Pierce, Rockford, IL, U.S.A.) as described by the manufacturer. Two anti-PrP C mAbs, 8B4 (N-terminus specific) and 8H4 (C-terminus specific), were used for the antibody coupling [37] . To enrich the fulllength PrP C , the 8B4-coupled Protein G column was incubated with brain homogenate at 4 mC overnight : after washing three times with PBS the bound full-length PrP C was eluted with 0.1 M glycine, pH 2.7. The flow-through, which contained only Nterminally truncated PrP C , was further incubated with 8H4-coupled affinity column ; the bound N-terminally truncated PrP C was also eluted with 0.1 M glycine, pH 2.7. The column-enriched full-length and N-terminally truncated PrP C s were quantified with immunoblots and ELISA [37] .
SDS/PAGE and immunoblotting
For SDS\PAGE, enriched full-length or N-terminally truncated human brain PrP C species were mixed with 2iSDS loading buffer (160 mM Tris, 4 % SDS, 4 % 2-mercaptoethanol, 20 % glycerol and 0.04 % Bromophenol Blue, pH 6.8), heated for 10 min at 95 mC, then loaded on to an SDS\PAGE gel (15 % ; Bio-Rad, Hercules, CA, U.S.A.). After electrophoresis, SDS\ PAGE slabs were electrotransferred on to nitrocellulose membranes and immunoblotted as described in [38] . Transferred PrP C was detected using mAb 8H4 in combination with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG Fc regionspecific antibody as the secondary antibody. PrP visualization was performed using the chemiluminescence blotting system (Roche, Indianapolis, IN, U.S.A.).
Detection of PrP binding to GAGs by ELISA
We established an ELISA to study PrP binding to GAGs. Chondroitin sulphate A (from bovine trachea), chondroitin sulphate B (from porcine intestinal mucosa), hyaluronic acid (from rooster comb) and heparin (from porcine intestinal mucosa ; all from Sigma, St. Louis, MO, U.S.A.) were coated on to flat-bottomed, 96-well Costar plates (Corning, Corning, NY, U.S.A.) at 2 µg\well at 4 mC overnight, and blocked with 3 % BSA in PBS at room temperature for 2 h. Plates coated with BSA (Sigma) were used as controls. Pre-determined amounts of recombinant rPrP, including rPrP #$ -#$" (full-length), rPrP #$ -"%& (C-terminally truncated) and rPrP *! -#$" (N-terminally truncated) or brain PrP C (in 10 mM Hepes\NaOH\100 mM NaCl, pH 7.5), were incubated with the coated plate for 1-2 h. After three washes with PBS containing 0.05 % Tween-20, the bound rPrP was detected with mAbs 8H4 or 8B4. Bound mAbs were detected with an HRP-conjugated goat anti-mouse IgG (Chemicon, Temecula, CA, U.S.A.). A %!& values were measured for 2,2h-azinobis-(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS ; Roche).
For the GAG-binding competition studies, the rPrP (0.1 µg\ml) was incubated with GAG-coated plates in the presence of various amounts of free GAGs or heparin analogues (Sigma) as indicated in the individual experiments.
To study the effect of divalent cations on GAG binding, prior to binding to the GAG-coated ELISA plates, different concentrations of divalent cation solutions, including CuCl
and MnCl # (Sigma), were incubated with full-length or truncated PrP (0.1 µg\ml, 0.1 ml\well) for at least 2 h, as indicated in individual experiments. All experiments were carried out in duplicate and repeated a minimum of three times.
Binding of biotinylated heparin to PrP synthetic peptides
To identify the amino acid sequence in PrP that binds heparin, we established an ELISA using biotinylated heparin and synthetic PrP peptides. Heparin was biotinylated using the EZ-link Sulpho-NHS-Biotin kit (Pierce). Each PrP peptide has 13 amino acid residues, and overlaps with the next peptide by three amino acids. The panel of peptides covers the N-terminus of PrP from residue 23 to 146 (Princeton Biomolecules, Langhorne, PA, U.S.A.). The peptides used are listed here :
& each contain one of the octapeptide repeats (as indicated by an underscore). We did not use the two overlapping peptide '$ -(& and peptide )$ -*& . Each PrP peptide was coated at 1 µg\well on to a 96-well plate, and incubated at 4 mC overnight. The coated plate was blocked with 3 % BSA in PBS at room temperature for 2 h. Different amounts of biotinylated heparin were added to the wells, followed by incubation at room temperature for 1 h. With extensive washing, the bound biotinylated heparin was detected by HRPconjugated streptavidin. A values at 405 nm were measured for ABTS (Roche). The plate included duplicate wells, and the experiment was repeated at least three times.
Immunofluorescent staining and flow cytometry analysis
To detect heparin binding to various cell lines, 1i10' cells were washed and suspended in a washing buffer (PBS with 5 % calf serum and 0.1 % NaN $ , pH 7.5), followed by incubation with 1-2 µg of biotinylated heparin on ice for 1 h. After extensive washing, the bound biotinylated heparin was detected by phycoerythrin-conjugated strepavidin. The stained cells were analysed with FACScan (Becton Dickinson, Mountain View, CA, U.S.A.). To demonstrate the binding specificity, biotinylated heparin was also used to stain WV cells in the presence of different concentrations of unlabelled heparin.
To detect the binding of hyaluronic acid to WV cells, WV cells were stained with FITC-conjugated hyaluronic acid, and analysed with FACScan similarly. FITC-conjugated hyaluronic acid was prepared as described in [39] .
For the detection of cell-surface PrP C , various M17-PrP and M17 cells were stained with mAb 8H4 or 8B4 followed by FITCconjugated goat anti-mouse IgG Fc region-specific antibody (Chemicon) before analysis by FACScan. All experiments were repeated at least three times with comparable results.
Binding of heparin reduces the levels of cell-surface PrP C
The parental M17 cell line and various M17-PrP transfectants were incubated with heparin at 0, 1 or 10 µg\ml in RPMI media for 12 h. After fixation in 3 % paraformaldehyde, cell-surface PrP C was measured by immunofluorescent staining with mAb 8H4 as described earlier.
RESULTS

Binding of rPrP to GAGs is mediated by the N-terminus of PrP
We used a full-length recombinant rPrP #$ -#$" , an N-terminally truncated rPrP *! -#$" and a C-terminally truncated rPrP #$ -"%& to study the binding of rPrP to GAGs by ELISA. In the first series of experiments, ELISA plates were coated with heparin ; different amounts of rPrP
were then added on to the
Figure 1 Binding of rPrP to heparin
We compared the abilities of various forms of bacterially produced rPrP to bind heparin in ELISA. ELISA plates were first coated with heparin. The binding of full-length rPrP (A) and an N-terminally truncated form, rPrP 90-231 (B), to heparin was compared and measured by mAb 8H4 and HRP-conjugated goat anti-mouse IgG1, while the binding of full-length (C) versus C-terminally truncated rPrP (D) was compared using mAb 8B4 and HRP-conjugated goat anti-mouse IgG1. In both cases, plates coated with BSA were used as controls. Only full-length rPrP and C-terminally truncated rPrP bind strongly to heparin, while none of the rPrPs bind significant levels of BSA or polyglutamic acids (results not shown plate. After extensive washing, bound rPrP was detected with mAb 8H4, which reacts with an epitope located in the Cterminus between PrP amino acid residues 176 and 185. As a control, BSA was used. We found that full-length rPrP #$ -#$" bound heparin ( Figure 1A ) much more strongly than Nterminally truncated rPrP *! -#$" ( Figure 1B ). The N-terminally truncated rPrP *! -#$" only exhibits binding at the highest concentration and the binding is much weaker. Neither rPrP #$ -#$" nor rPrP *! -#$" bind BSA (result not shown). Therefore, rPrP binding to heparin is specific.
Next we compared rPrP #$ -#$" binding ( Figure 1C ) and Cterminally truncated rPrP #$ -"%& binding ( Figure 1D ) to heparin. We detected the bound rPrP with mAb 8B4, which reacts with an epitope located between residues 34 and 45 in the N-terminus. We found that both rPrP #$ -#$" and rPrP #$ -"%& bind heparin ( Figure  1D ). We also examined the ability of rPrP to bind three other GAGs : chondroitin sulphate A, chondroitin sulphate B and hyaluronic acid, and the results were similar to those for heparin. Binding of GAGs to rPrP under our experimental conditions is not due to the charge properties of GAGs. rPrP does not bind ELISA plates similarly coated with polyglutamic acid (results not shown). Collectively, these results show that the N-terminus is the region of the rPrP molecule that binds GAGs.
Inhibition of heparin binding with GAGs, heparin polymers, disaccharides and monosaccharides
We next determined whether binding of full-length rPrP to heparin could be inhibited by other GAGs as well as certain heparin analogues (Figure 2) . Free chondroitin sulphate A, chondroitin sulphate B and hyaluronic acid all inhibited the binding of full-length PrP to immobilized heparin. However, compared with soluble heparin itself, the other three GAGs are much weaker inhibitors (Figure 2, top panel) . These results suggested that the interaction between heparin and PrP is stronger than the interaction between PrP and other GAGs. Besides heparin itself, low-molecular-mass heparin, heparin disaccharides and several types of monosaccharide (such as -glucosamine 2,6-disulphate, -glucosamine 2-sulphate and -glucosamine 6-sul-
Figure 3 Effects of divalent metal ions on rPrP binding to heparin
To study the role that divalent metal ions play in PrP binding to GAGs, full-length rPrP (A) and C-terminally truncated rPrP phate) also inhibited PrP binding to immobilized heparin ( Figure  2 , middle and bottom panels). Chemical modification of amine groups on heparin by acetylation significantly reduces its inhibitory activity, as compared with other heparin polymers, which may be due to the decreased negative charges (Figure 2 , middle panel). Monosaccharides such as glucose, glucosamine and glucuronic acid do not inhibit binding (Figure 2 , bottom panel). Therefore, the presence of the sulphate group is important in GAG binding to rPrP.
Enhancement of heparin binding by divalent cations
The N-terminus of PrP binds metals [13] . We investigated the effects of divalent cations such as Cu# + , Zn# + , Ca# + and Mn# + on Cell-surface prion protein interacts with glycosaminoglycans the binding of rPrP #$ -#$" ( Figure 3A ) or rPrP #$ -"%& ( Figure 3B ) to heparin. We found that Cu# + and Zn# + , but not Ca# + or Mn# + , enhance the binding of rPrP #$ -#$" and rPrP #$ -"%& to heparin. Enhanced binding is cation-concentration-dependent, and can be detected at concentrations as low as 40 µM CuCl # or ZnCl # . None of the metals has any affect on rPrP *! -#$" binding to GAGs (results not shown). Therefore, the enhancement seen with Cu# + or Zn# + is specific for rPrP #$ -#$" . Cu# + and Zn# + , but not Mn# + , also enhance the binding of rPrP to other GAGs (results not shown).
Brain-derived full-length PrP C species bind heparin and binding is enhanced by divalent cations
We investigated whether the observations made using rPrP are applicable to native PrP C isolated from human brain. We used an N-terminus-specific mAb, 8B4, and a C-terminus-specific mAb, 8H4, to purify full-length human brain PrP C species and the Nterminally truncated PrP C species [38] . After affinity purification, we confirmed the identities of the PrP species using immunoblots. On SDS\PAGE, the full-length brain PrP C species appeared as a single 35 kDa band ( Figure 4A , lane 2) while N-terminally truncated PrP C species contained multiple bands with molecular masses ranging from 18 to 30 kDa ( Figure 4B, lane 2) .
We next determined the ability of the purified full-length PrP C species and the N-terminally truncated PrP C species to bind GAGs in the ELISA. Consistent with the results using rPrP, we found that only the full-length PrP C bound heparin ( Figure 4A ). The N-terminally truncated PrP C species did not bind heparin at all ( Figure 4B ). Similar to full-length rPrP #$ -#$" and C-terminally truncated rPrP #$ -"%& , the binding of full-length native PrP C species from human brain is also enhanced by divalent metal ions such as Cu# + ( Figure 5A ) and Zn# + (Figure 5B ), but not Mn# + (results not shown). The enhanced binding is also dependent on the concentration of the cations ( Figure 5) .
Figure 5 Effects of divalent metal ions on native PrP C binding to heparin
Identification of the GAG-binding motif on rPrP
We investigated whether GAGs bind to a panel of synthetic peptides corresponding to amino acids 23-146 of PrP. Each synthetic peptide is comprised of 13 amino acids and overlaps with the neighbouring peptide by three residues. We found that heparin bound high levels of synthetic peptides that contain amino acids 23-35 ( Figure 6A ). The binding of heparin to this peptide is concentration-dependent ( Figure 6B ). This peptide has a stretch of four basic amino acid residues spanning positions 23-27, KKRPK (the basic residues are underlined), which is very similar to the consensus sequence for heparin binding [40] . Weaker binding was detected with synthetic peptides that contain residues 33-45. Much weaker binding was detected with synthetic peptides corresponding to residues 43- 
Heparin binding to cell-surface PrP C
PrP C is normally present at the cell surface as a glycosylphosphatidylinositol-anchored protein.
To establish the biological significance of the in itro results, we next investigated whether heparin could bind cell-surface PrP C . We used
Figure 6 Binding of biotinylated heparin to synthetic PrP peptides
To identify the amino acid sequence responsible for heparin binding in PrP, we coated ELISA plates with a panel of synthetic PrP peptides corresponding to amino acids 23-146. Each peptide had 13 amino acid residues. We determined whether biotinylated heparin was able to bind any of these synthetic peptides. High level of binding was detected with peptide [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Lower levels of binding were also detected with four other peptides (A). Binding to peptide [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] is specific and dependent on heparin dosage (B). These results provide conclusive evidence that the extreme N-terminus of rPrP binds GAGs. O.D. 405 represents A 405 .
biotinylated heparin to study heparin binding to a panel of cell lines that have been transfected to express either human wildtype PrP C or mutant PrP C : (i) M17 is the parental cell line that does not express PrP C ; (ii) WV is a cell line that expresses wildtype human PrP C with a Val at position 129 ; (iii) δ8 is a cell line that expresses a mutated human PrP C in which the octapeptide repeats have been deleted ; and (iv) VT is another cell line that expresses a human PrP C , in which the N-terminal domain at residues 23-90 has been deleted. The PrP expression levels in the cell lines WV, VT and δ8 are similar, as demonstrated by mAb 8H4 staining ( Figure 7A ). Only WV and δ8 contain the N-terminus, as demonstrated by the Nterminus-specific mAb 8B4 ( Figure 7B ). As expected, WV and δ8 can bind biotinylated heparin intensively ( Figure 7C ), while the parental M17 cell line, which lacks PrP C , binds heparin much more weakly. These results confirmed our earlier findings on rPrP that the octapeptide sequence is not essential for GAG binding. Binding of heparin to WV cells is specific, for neither polyglutamic acids nor BSA could inhibit the binding of biotinylated heparin (results not shown). On the other hand, unlabelled heparin inhibited the binding of biotinylated heparin in a concentration-dependent manner ( Figure 8A ). The inability of polyglutamic acids to block binding of heparin provides additional support for our conclusion that binding of PrP C to GAGs is not solely mediated by the charge properties of GAGs.
Another GAG, FITC-conjugated hyaluronic acid, also binds WV cells, but not the parental M17 cells ( Figure 8B) .
GAGs have been demonstrated to induce the endocytosis of chicken PrP C [27] . We next investigated whether incubation with heparin reduces the levels of wild-type PrP C on the cell surface. We found that incubation of WV cells with heparin significantly reduced the immunoreactivity of PrP C on the cell surface, as detected by mAb 8H4, which reacts with an epitope in the C-terminus of PrP C (Figure 8C ). On the other hand, addition of heparin to VT cells, which do not bind heparin, has no effect on the immunoreactivity of cell-surface PrP C ( Figure 8D) . From these experiments, we concluded that binding of heparin to cellsurface PrP C reduces the level of surface PrP C on WV cells.
DISCUSSION
In this study, we demonstrated that binding of PrP to GAGs is mediated by a sequence in its N-terminus, a region that has also been implicated in metal binding [13, 41] . The observation that Cu# + and Zn# + enhance PrP binding to GAGs, but that Mn# + does not, raises several interesting points about the binding of metals to PrP. Although it is known that the N-terminus of PrP binds metals, the specificity of that binding is still a matter of debate. Some studies showed that PrP binds Cu# + , Zn# + and Mn# + [42] , whereas others showed PrP only binds Cu# + [41] . In this study, we demonstrate that Cu# + and Zn# + enhance PrP binding of GAGs, but not Mn# + . If PrP binds Mn# + , as has been reported [42] , why is Mn# + unable to enhance the binding of PrP to GAGs ? One possibility is that the affinity of PrP for Mn# + may be too low, as shown by others [42] . Alternatively, Mn# + may be unable to bind to our PrP, since binding of Mn# + to PrP is known to be dependent on the conformation of PrP [43] . Lastly, PrP may bind Cu# + , Zn# + and Mn# + , but the conformation of Cu# + -bound PrP and Mn# + -bound PrP may be different. Only the conformations adopted by Cu# + -and Zn# + -bound PrP have an increased capacity to bind GAGs.
As we have demonstrated, the metal-binding site and the dominant GAG-binding sites on PrP are different. We identified the GAG-binding motif on PrP using a panel of overlapping synthetic peptides. Of all the synthetic peptides tested, including those from octapeptide repeat regions, only one was able to bind high levels of GAGs. This peptide contains a sequence that includes amino acid residues 23-35. This region contained a motif of four basic residues, KKRPK, which we hypothesize is the site where GAGs bind. This motif is very similar to an identified consensus heparin-binding motif, which contains six amino acids that are basic, basic, basic, non-basic, non-basic and basic residues [40] . Much weaker bindings were observed with synthetic peptides of residues 33-65 and 103-115. The consensus heparin-binding motif is absent in the octapeptide repeat region.
Although the exact mechanism by which Cu# + and Zn# + enhance the binding of GAG is not known, it is possible that the binding of metals may increase or even stabilize the exposure of the GAG-binding motif on the N-terminus. This interpretation is supported by our earlier findings, which indicates that refolding of rPrP #$ -#$" in the presence of Cu# + increases the binding of an anti-PrP mAb 5B2 [44] . The epitope of mAb 5B2 is located between residues 35 and 45, adjacent to the GAG-binding motif. Alternatively, Cu# + is known to cause intermolecular interactions between rPrP molecules [45] . These interactions may promote binding of GAGs.
Earlier studies suggested that Cu# + -bound PrP has SOD-like activity [15] . It is believed that binding of Cu# + to PrP at the octapeptide repeats results in a conformational change in the C-terminus, which is the domain that mediates the SOD-like activity. The results presented here suggest that binding of metals to PrP can have multiple effects on PrP, resulting in both conformational and functional changes in the N-terminus as well as the C-terminus of PrP. The enhanced binding of PrP to GAGs by Cu# + can be observed at 40-500 µM, which is within the physiological levels of Cu# + in the brain [41] . We also observed that while full-length PrP C species derived from human brain bind all GAGs tested, the N-terminally truncated PrP C species did not. Binding of GAGs is also increased in the presence of either Cu# + or Zn# + but not Mn# + . However, maximum enhancement of GAG binding of full-length, brain-derived PrP C appears to require a higher concentration of Cu# + and Zn# + . Although we observed low levels of rPrP *! -#$" binding to GAGs, no physical association between GAGs and N-terminally truncated PrP C species derived from human brain was detected. As most of the N-terminally truncated PrP C species in human brain are truncated at around residue 110 [46] , it is conceivable that rPrP *! -#$" may contain additional GAG-binding sites. Interestingly, the synthetic peptide that spans amino acid residues 103-115 binds weakly to GAGs. We recently found that in human brain most of the PrP C species are N-terminally truncated [47] . We further suggest that truncation may be a process by which PrP C function is regulated. Based on the results presented here, we speculate that one of the consequences of truncation would be to render the PrP C molecule unable to bind GAGs.
Some polyanions have been reported to prolong the incubation period in experimentally infected mice [24, 25] , presumably by interfering with the binding of PrP Sc to PrP C . We report here that binding of GAGs to PrP C is inhibited by heparin disaccharideand sulphate-containing monosaccharides such as -glucosamine 6-sulphate and -glucosamine 2,6-disulphate. In contrast, monosaccharides such as -glucose, -glucuronic acid or -glucosamine, which lack sulphate, were ineffective. These results suggest that the negatively charged sulphate group is important in the binding of GAG to PrP C . Presumably the negatively charged sulphate group interacts with the four basic residues KKRPK in the N-terminus. However, PrP C also binds hyaluronic acid, which lacks sulphate groups. The fact that acetylated heparin is a less effective inhibitor than heparin and low-molecular-mass heparin may also be due to the reduction in sulphate groups present.
Polyanions have been used therapeutically to delay the onset of prion diseases. We hypothesize that in i o injection of sulphate-containing monosaccharide may provide significant therapeutic advantages ; monosaccharides tend to have a longer in i o half-life, have fewer side effects and are much more likely to cross the blood-brain barrier. Experiments are now in progress to determine whether these sulphate-containing monosaccharides can prolong the latency period in experimentally infected mice. While monosaccharide can compete for binding of GAG to rPrP, the synthetic peptide that contains residues 23-35 cannot compete with rPrP for binding to GAGs (results not shown). This is most likely due to the fact that in each GAG molecule there are multiple PrP-binding sites. On the other hand, each PrP molecule has only one dominant GAG-binding site.
Figure 8 Heparin-PrP interaction induced cell-surface PrP down-regulation
The WV cells strongly bound biotinylated heparin (A, trace 1), while control cells did not (A, shaded peak). This binding can be specifically inhibited by the addition of un-conjugated heparin at 10 µg/ml (A, trace 3) or 1 µg/ml (A, trace 2). WV cells also bound FITC-conjugated hyaluronic acid (B, thick trace), while the parental M17 cell line did not (B, shaded peak). These results provide direct evidence that cell-surface PrP C is a receptor for heparin and hyaluronic acid. The level of cell-surface PrP decreased in WV cells (C, trace 1) but not in VT (D), when incubated with heparin at 10 mg/ml (C, trace 3) and 1 mg/ml (C, trace 2) for 12 h. The shaded peaks in the histograms are non-transfected controls. The PrP was detected by mAb 8H4 staining.
We demonstrated that cell-surface PrP C binds heparin and hyaluronic acid. The fact that WV and δ8 cell lines bind heparin is consistent with our findings with rPrP and human brainderived PrP C . We believe that it is the N-terminus of cell-surface PrP C that binds heparin and hyaluronic acid. Attempts to block binding of GAG with many anti-PrP mAbs were unsuccessful. However, mAb 8B4 slightly decreased the binding of heparin (results not shown). mAb 8B4 reacts with an epitope between residues 33 and 44, an area adjacent to the GAG-binding motif [37] . A mAb that reacts with amino acid residues from 23 to 35, which we do not have, should be able to block GAG binding. Another cell-surface molecule known to bind hyaluronic acid is CD44 [39] . However, the M17 neuroblastoma cells do not express CD44 (results not shown). Therefore, binding of hyaluronic acid to WV cells is not mediated by CD44 but is PrP Cdependent.
It is known that heparin and hyaluronic acid participate in cell signalling. Binding of heparin is essential for the functions of some growth factors, such as fibroblast growth factor [48] . GAGs may cross-link cell-surface PrP C , and may result in the downstream signalling events. We showed that the cross-linking of PrP C on human lymphocytes by anti-PrP mAb could indeed influence cell signalling [49] . PrP C has also been shown to participate in signalling in neurons [50] . High levels of GAGs are present in the extracellular matrix in the central nervous system. GAG-containing proteoglycans are also present on the cell surface. We hypothesize that interactions between PrP C on one cell and GAGs in the extracellular matrix, or on the surface of another cell, may be important in cell-cell adhesion and signalling. While GAGs bind PrP C on the cell surface, the mechanism by which binding of GAGs reduces the cell-surface levels of PrP C is not known. We were unable to demonstrate consistently the internalization of GAG-PrP C complex from the cell surface (results not shown). Alternatively, binding of GAGs may also result in the shedding of the complex from the cell surface.
Finally, our findings may also have relevance to the pathogenesis of prion diseases. Recently, we reported that PrP species isolated from Creutzfeldt-Jakob disease patients have increased Mn# + , decreased Cu# + and reduced antioxidant activity [43] . Therefore, we hypothesize that an alteration in the metal content of PrP can not only cause the loss of antioxidant functions, but it can also influence PrP binding to GAGs. Both of these events may contribute to the pathogenesis of prion diseases.
